What is Lifesci Capital's Estimate for TCRX FY2025 Earnings?

Key Points

• Lifesci Capital has revised its FY2025 earnings estimate for TScan Therapeutics, now predicting a loss of $1.16 per share, down from $1.10.
• The consensus estimate for TScan's full-year earnings stands at ($1.12) per share, with current stock ratings showing a "Moderate Buy" sentiment.
• TScan Therapeutics reported a revenue of $3.08 million for the last quarter, significantly exceeding analysts' expectations of $1.31 million.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Stock analysts at Lifesci Capital dropped their FY2025 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Thursday, August 14th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($1.16) for the year, down from their prior forecast of ($1.10). The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share.

A number of other brokerages have also commented on TCRX. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Wedbush reiterated an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Finally, HC Wainwright cut their target price on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, TScan Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Trading Up 7.5%

TCRX stock traded up $0.13 during midday trading on Monday, reaching $1.87. The stock had a trading volume of 353,254 shares, compared to its average volume of 254,039. The business has a fifty day simple moving average of $1.69 and a two-hundred day simple moving average of $1.64. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18. The firm has a market cap of $105.82 million, a price-to-earnings ratio of -1.72 and a beta of 0.99. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $6.2250.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, hitting analysts' consensus estimates of ($0.28). The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TCRX. JPMorgan Chase & Co. increased its holdings in shares of TScan Therapeutics by 109.9% in the fourth quarter. JPMorgan Chase & Co. now owns 66,756 shares of the company's stock worth $203,000 after acquiring an additional 34,951 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after acquiring an additional 5,694 shares in the last quarter. Barclays PLC increased its holdings in shares of TScan Therapeutics by 16.3% in the fourth quarter. Barclays PLC now owns 67,508 shares of the company's stock worth $206,000 after acquiring an additional 9,441 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of TScan Therapeutics by 108.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after acquiring an additional 145,731 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in TScan Therapeutics by 10.7% during the 4th quarter. Stifel Financial Corp now owns 109,700 shares of the company's stock worth $333,000 after buying an additional 10,567 shares during the period. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.